scholarly journals Does Locoregional Chemotherapy Still Matter in the Treatment of Advanced Pelvic Melanoma?

2017 ◽  
Vol 18 (11) ◽  
pp. 2382 ◽  
Author(s):  
Stefano Guadagni ◽  
Giammaria Fiorentini ◽  
Marco Clementi ◽  
Giancarlo Palumbo ◽  
Paola Palumbo ◽  
...  
Keyword(s):  
Locoregional Chemotherapy

Attempts to improve locoregional chemotherapy for the prevention of colonic cancer liver metastasis in the rat

2006 ◽  
Vol 30 (8-9) ◽  
pp. 1019-1025 ◽  
Author(s):  
Laurent Benoit ◽  
Patrick FavouletP ◽  
Pablo Ortega-Deballon ◽  
Nicolas Cheynel ◽  
Anisoara Anusca ◽  
...  
Keyword(s):  
Liver Metastasis ◽  
Colonic Cancer ◽  
Locoregional Chemotherapy

Locoregional Chemotherapy for Patients with Pancreatic Cancer Intra-arterial Adjuvant Chemotherapy After Pancreatectomy with Portal Vein Resection

Pancreas ◽  
2002 ◽  
Vol 25 (4) ◽  
pp. 366-372 ◽  
Author(s):  
Hiroki Yamaue ◽  
Masaji Tani ◽  
Hironobu Onishi ◽  
Hiroyuki Kinoshita ◽  
Mikihito Nakamori ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Adjuvant Chemotherapy ◽  
Portal Vein ◽  
Portal Vein Resection ◽  
Locoregional Chemotherapy ◽  
Vein Resection

scholarly journals Multidisciplinary Treatment, Including Locoregional Chemotherapy, for Merkel-Polyomavirus-Positive Merkel Cell Carcinomas: Perspectives for Patients Exhibiting Oncogenic Alternative Δ exon 6–7 TrkAIII Splicing of Neurotrophin Receptor Tropomyosin-Related Kinase A

2020 ◽  
Vol 21 (21) ◽  
pp. 8222
Author(s):  
Stefano Guadagni ◽  
Antonietta Rosella Farina ◽  
Lucia Annamaria Cappabianca ◽  
Michela Sebastiano ◽  
Rita Maccarone ◽  
...  
Keyword(s):  
Mrna Expression ◽  
Large Scale ◽  
Protein Extraction ◽  
Multidisciplinary Treatment ◽  
T Antigen ◽  
Neurotrophin Receptor ◽  
Merkel Cell ◽  
Locoregional Chemotherapy ◽  
Ffpe Tissues ◽  
Protein Isoform

Merkel cell carcinomas (MCCs) are rare, aggressive, cutaneous neuroendocrine tumours, approximately 80% of which are caused by the genomic integration of Merkel cell polyomavirus (MCPyV). MCPyV-positive MCCs carry poor prognosis in approximately 70% of cases, highlighting the need for greater understanding of the oncogenic mechanisms involved in pathogenesis, progression and post-therapeutic relapse, and translation into novel therapeutic strategies. In a previous pilot study, we reported a potential relationship between MCPyV gene expression and oncogenic alternative Δ exon 6–7 TrkAIII splicing in formalin-fixed paraffin-embedded (FFPE) MCC tissues from a 12-patient cohort of >90% MCPyV-positive MCCs, diagnosed at San Salvatore Hospital, L’Aquila, Italy, characterising a new MCC subgroup and unveiling a novel potential MCPyV oncogenic mechanism and therapeutic target. This, however, could not be fully verified due to poor RNA quality and difficulty in protein extraction from FFPE tissues. Here, therefore, we extend our previous observations to confirm the relationship between MCPyV and oncogenic alternative Δ exon 6–7 TrkAIII splicing in fresh, nonfixed, MCPyV-positive MCC metastasis by detecting sequence-verified RT-PCR products, including full-length Δ exon 6–7 TrkAIII, and by Western blot detection of a 100 kDa TrkA protein isoform of identical size to 100 kDa Δ exon 6–7 TrkAIII expressed by stable transfected SH-SY5Y cells. We also report that in three MCC patients submitted for multidisciplinary treatment, including locoregional chemotherapy, MCPyV large T-antigen mRNA expression, Δ exon 6–7 TrkAIII mRNA expression and intracellular indirect immunofluorescence (IF) TrkA and phosphorylation protein isoform(s) immunoreactivity in FFPE tissues were not reduced in postchemotherapeutic-relapsed MCCs compared to pretherapeutic MCCs, extending the possible roles of this novel potential MCPyV oncogenic mechanism from MCC pathogenesis to post-therapeutic relapse and progression. Detection of alternative Δ exon 6–7 TrkAIII splicing in MCC, therefore, not only characterises a new MCPyV-positive MCC subgroup and unveils a novel potential MCPyV oncogenic mechanism but also identifies patients who may benefit from inhibitors of MCPyV T-antigen and/or TrkAIII expression or clinically approved Trk kinase inhibitors such as larotrectinib or entrectinib, which are known to inhibit activated TrkA oncogenes and to elicit durable responses in TrkA-fusion oncogene-driven cancers, supporting the call for a large-scale multicentre clinical study.

Treatment of advanced malignant eccrine poroma with locoregional chemotherapy

2005 ◽  
Vol 152 (5) ◽  
pp. 1051-1055 ◽  
Author(s):  
E. de Bree ◽  
E. Volalakis ◽  
D. Tsetis ◽  
Y. Varthalitis ◽  
J. Panagiotidis ◽  
...  
Keyword(s):  
Locoregional Chemotherapy ◽  
Eccrine Poroma

ROS-sensitive thioketal-linked polyphosphoester-doxorubicin conjugate for precise phototriggered locoregional chemotherapy

Biomaterials ◽  
2019 ◽  
Vol 188 ◽  
pp. 74-82 ◽  
Author(s):  
Pei Pei ◽  
Chunyang Sun ◽  
Wei Tao ◽  
Jie Li ◽  
Xianzhu Yang ◽  
...  
Keyword(s):  
Locoregional Chemotherapy

scholarly journals Simultaneous sentinel lymph node computed tomography and locoregional chemotherapy for lymph node metastasis in rabbit using an iodine-docetaxel emulsion

Oncotarget ◽  
2017 ◽  
Vol 8 (16) ◽  
pp. 27177-27188 ◽  
Author(s):  
Honsoul Kim ◽  
Eun-Ji Jang ◽  
Sang Kyum Kim ◽  
Woo Jin Hyung ◽  
Dong Kyu Choi ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Lymph Node Metastasis ◽  
Node Metastasis ◽  
Locoregional Chemotherapy
Sign in / Sign up

Export Citation Format

Share Document